Dr\u00e4ger recognized for pioneering innovations in respiratory care, delivering measurable improvements in patient outcomes, clinical efficiency, cost-effectiveness and critical care training<\/i> <\/p>\n
SAN ANTONIO<\/span>, July 10, 2025<\/span> \/PRNewswire\/ —\u00a0Frost & Sullivan<\/a>\u00a0is pleased to announce that Dr\u00e4ger<\/a>\u00a0has received the 2025 Global Company of the Year Award in the respiratory devices industry for its outstanding achievements in clinical innovation, cost-effective solutions, customer-centric strategy execution, and global market impact. This recognition underscores Dr\u00e4ger’s continued leadership in transforming respiratory care through advanced technologies, comprehensive training programs, and a deep-rooted commitment to improving patient outcomes and caregiver wellness in intensive care environments.<\/p>\n Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: visionary innovation and customer impact. Dr\u00e4ger excelled in both, demonstrating its ability to align its innovation roadmap with market demand while executing with precision, scalability, and clinical relevance. “Keeping the customer need in mind, Dr\u00e4ger’s designs focus on a range of consumer needs, including scalability, flexibility, low infection rates, low readmission rates, reduced costs, high return on investment for healthcare providers, workplace safety, process improvement, human error reduction, enhanced patient and family experiences, patient comfort, and operational efficiencies,” said Utkarsha Soundankar, Industry Analyst at Frost & Sullivan.<\/p>\n Guided by a long-term growth strategy focused on digital innovation, clinical partnerships, and value-based care, Dr\u00e4ger has demonstrated its ability to lead in a rapidly evolving respiratory care landscape. The company’s sustained investment in smart ventilator technology, workflow integration, and clinician training has enabled it to scale its solutions across diverse healthcare systems globally.<\/p>\n Innovation remains at the heart of Dr\u00e4ger’s approach. Its V-Series ventilators\u2014featuring SmartCare\/PS, integrated capnography, proportional pressure support, and high-flow oxygen therapy\u2014are purpose-built to support the improvement of clinical outcomes, reduce the duration of mechanical ventilation, and support bundled payment models. Dr\u00e4ger’s recent achievement in securing Authority to Operate (ATO) certification for its Evita V800\/V600, Babylog VN800, and Savina 300 ventilators from the US Department of Defense marks a significant milestone in medical device security, interoperability, and deployment in mission-critical environments.<\/p>\n “Given the recent wave of market consolidation of vendors in the ventilation market, today’s decision makers are seeking more than just high-quality devices\u2014they’re looking for trusted partners who are deeply committed to supporting the respiratory care community,” said Lothar Thielen, President and CEO of Draeger, Inc. “This award is a powerful affirmation of Dr\u00e4ger’s unwavering commitment to our customers to deliver exceptional value through a combination of industry-leading products, cost-effective accessories and comprehensive service solutions that help hospitals provide the highest standard of care.”<\/p>\n In addition to product innovation, Dr\u00e4ger is redefining the respiratory care ecosystem through its full-service offerings, including responsive maintenance programs, biomedical training, and digital education platforms.<\/p>\n In 2024, the company introduced Dr\u00e4ger Virtuo, an immersive virtual reality platform for ICU, OR, and NICU training, unveiled at the American Association for Respiratory Care (AARC) Congress. Alongside this launch, the revitalized Dr\u00e4ger Academy continues to expand its impact by delivering more than 84,500 hours of CRCE credits annually and offering micro-learning modules tailored for clinicians’ evolving needs. This integrated education model is designed to build clinical confidence and ensure rapid onboarding and knowledge retention\u2014imperative in high-stakes care environments.<\/p>\n Frost & Sullivan commends Dr\u00e4ger for setting the benchmark in strategic execution and customer-focused innovation in the respiratory devices industry. The company’s holistic approach\u2014combining clinical-grade technology, secure deployment, and professional development\u2014continues to support redefining the standard for excellence in respiratory care. Its ability to aid in improving clinical workflows, lowering total cost of care, and expanding access to next-generation training aims to ensure lasting impact across global healthcare ecosystems.<\/p>\n Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. It recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.<\/p>\n Frost & Sullivan Best Practices recognitions honor companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.<\/p>\n About Frost & Sullivan<\/b> <\/p>\n For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success.\u00a0Contact us: Start the discussion<\/a>.<\/p>\n Contact: Dr\u00e4ger. Technology for Life <\/p>\n Dr\u00e4ger recognized for pioneering innovations in respiratory care, delivering measurable improvements in patient outcomes, clinical efficiency, cost-effectiveness and critical care training<\/i> <\/p>\n SAN ANTONIO<\/span>, July 10, 2025<\/span> \/PRNewswire\/ —\u00a0Frost & Sullivan<\/a>\u00a0is pleased to announce that Dr\u00e4ger<\/a>\u00a0has received the 2025 Global Company of the Year Award in the respiratory devices industry for its outstanding achievements in clinical innovation, cost-effective solutions, customer-centric strategy execution, and global market impact. This recognition underscores Dr\u00e4ger’s continued leadership in transforming respiratory care through advanced technologies, comprehensive training programs, and a deep-rooted commitment to improving patient outcomes and caregiver wellness in intensive care environments.<\/p>\n Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: visionary innovation and customer impact. Dr\u00e4ger excelled in both, demonstrating its ability to align its innovation roadmap with market demand while executing with precision, scalability, and clinical relevance. “Keeping the customer need in mind, Dr\u00e4ger’s designs focus on a range of consumer needs, including scalability, flexibility, low infection rates, low readmission rates, reduced costs, high return on investment for healthcare providers, workplace safety, process improvement, human error reduction, enhanced patient and family experiences, patient comfort, and operational efficiencies,” said Utkarsha Soundankar, Industry Analyst at Frost & Sullivan.<\/p>\n Guided by a long-term growth strategy focused on digital innovation, clinical partnerships, and value-based care, Dr\u00e4ger has demonstrated its ability to lead in a rapidly evolving respiratory care landscape. The company’s sustained investment in smart ventilator technology, workflow integration, and clinician training has enabled it to scale its solutions across diverse healthcare systems globally.<\/p>\n Innovation remains at the heart of Dr\u00e4ger’s approach. Its V-Series ventilators\u2014featuring SmartCare\/PS, integrated capnography, proportional pressure support, and high-flow oxygen therapy\u2014are purpose-built to support the improvement of clinical outcomes, reduce the duration of mechanical ventilation, and support bundled payment models. Dr\u00e4ger’s recent achievement in securing Authority to Operate (ATO) certification for its Evita V800\/V600, Babylog VN800, and Savina 300 ventilators from the US Department of Defense marks a significant milestone in medical device security, interoperability, and deployment in mission-critical environments.<\/p>\n “Given the recent wave of market consolidation of vendors in the ventilation market, today’s decision makers are seeking more than just high-quality devices\u2014they’re looking for trusted partners who are deeply committed to supporting the respiratory care community,” said Lothar Thielen, President and CEO of Draeger, Inc. “This award is a powerful affirmation of Dr\u00e4ger’s unwavering commitment to our customers to deliver exceptional value through a combination of industry-leading products, cost-effective accessories and comprehensive service solutions that help hospitals provide the highest standard of care.”<\/p>\n In addition to product innovation, Dr\u00e4ger is redefining the respiratory care ecosystem through its full-service offerings, including responsive maintenance programs, biomedical training, and digital education platforms.<\/p>\n In 2024, the company introduced Dr\u00e4ger Virtuo, an immersive virtual reality platform for ICU, OR, and NICU training, unveiled at the American Association for Respiratory Care (AARC) Congress. Alongside this launch, the revitalized Dr\u00e4ger Academy continues to expand its impact by delivering more than 84,500 hours of CRCE credits annually and offering micro-learning modules tailored for clinicians’ evolving needs. This integrated education model is designed to build clinical confidence and ensure rapid onboarding and knowledge retention\u2014imperative in high-stakes care environments.<\/p>\n Frost & Sullivan commends Dr\u00e4ger for setting the benchmark in strategic execution and customer-focused innovation in the respiratory devices industry. The company’s holistic approach\u2014combining clinical-grade technology, secure deployment, and professional development\u2014continues to support redefining the standard for excellence in respiratory care. Its ability to aid in improving clinical workflows, lowering total cost of care, and expanding access to next-generation training aims to ensure lasting impact across global healthcare ecosystems.<\/p>\n Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. It recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.<\/p>\n Frost & Sullivan Best Practices recognitions honor companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.<\/p>\n About Frost & Sullivan<\/b> <\/p>\n For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success.\u00a0Contact us: Start the discussion<\/a>.<\/p>\n Contact: Dr\u00e4ger. Technology for Life <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-26872","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/26872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=26872"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/26872\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=26872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=26872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=26872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Ashley Shreve
E:\u00a0ashley.weinkauf@frost.com<\/a><\/p>\n
<\/b>Dr\u00e4ger is a leading international medical and safety technology company. Our products protect, support and save lives. Founded in L\u00fcbeck, Germany in 1889, Dr\u00e4ger generated global sales of around EUR 3 billion in 2022. The L\u00fcbeck-based company is represented in more than 190 countries and employs more than 14,000 people worldwide. For more information, visit www.draeger.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"
Ashley Shreve
E:\u00a0ashley.weinkauf@frost.com<\/a><\/p>\n
<\/b>Dr\u00e4ger is a leading international medical and safety technology company. Our products protect, support and save lives. Founded in L\u00fcbeck, Germany in 1889, Dr\u00e4ger generated global sales of around EUR 3 billion in 2022. The L\u00fcbeck-based company is represented in more than 190 countries and employs more than 14,000 people worldwide. For more information, visit www.draeger.com<\/a><\/p>\n